.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Molecular engineering has enabled the creation of advanced NIR-II phototheranostic agents for precise cancer management. Researchers recently developed a novel ionic small-molecule agent called 2PyI. By carefully balancing positive charges and hydrophilicity, they achieved an optimal amphiphilic structure. Consequently, this innovation allows for high-resolution imaging and powerful therapeutic effects.
The 2PyI agent provides several critical functions within a single molecule. First, it enables efficient NIR-II emission, which is essential for deep-tissue imaging. Furthermore, it produces reactive oxygen species to destroy malignant cells. It also facilitates photothermal conversion to generate localized heat. Therefore, this synergistic approach enhances the efficacy of both photodynamic and photothermal therapies.
In addition to its therapeutic power, the high-resolution imaging guides clinicians during treatment. Traditional imaging methods often struggle with deep-seated tumors. However, NIR-II light penetrates biological tissues much more effectively than visible light. Because of this, the new agent offers a promising platform for image-guided oncology. Ultimately, such molecular engineering paves the way for more effective and less invasive cancer treatments.
NIR-II imaging uses the second near-infrared window to provide deep tissue penetration and high resolution. This allows doctors to locate tumors more accurately than with conventional imaging.
It combines photodynamic therapy, which uses light to create reactive oxygen species, with photothermal therapy, which generates heat. Together, they provide a more potent effect against cancer cells.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Gong J et al. Molecular engineering of ionic organic phototheranostic agents for NIR-II imaging-guided synergistic phototherapy. Chem Commun (Camb). 2026 Feb 23. doi: 10.1039/d6cc00306k. PMID: 41725580.
Zhang X, et al. Recent advances in near-infrared-II (NIR-II) small molecule fluorophores for cancer theranostics. Journal of Materials Chemistry B. 2025.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers develop 2PyI, an ionic small-molecule agent for high-resolution NIR-II imaging and synergistic photodynamic/photothermal therapy....
5 months ago
New toxicological research evaluates heavy metal contamination in encapsulated green tea supplements, revealing that lead intake can exceed permitted daily exposure limits. The findings highlight the critical need for exposure-based risk assessment in botanical formulations.
Today
A prospective study evaluates the fetal Evans Index in late-onset fetal growth restriction, uncovering anterior cerebral remodeling rather than ventriculomegaly, with conventional growth metrics retaining primary prognostic power for neonatal intensive care unit admission.
Today
Following the admission of Union Health Minister JP Nadda to AIIMS Delhi for acute uneasiness, clinical teams utilized diagnostic coronary angiography and inpatient observation. This clinical review outlines acute triage pathways, procedural protocols, post-procedure observation, and long-term risk management.
Today
Recent research assesses an automated pipeline for CT-based vertebral finite element analysis, revealing how boundary condition components—especially load-point assignment—impact fracture-load accuracy in spinal biomechanics.
Today
Diabetic kidney disease remains a major cause of renal failure despite renin-angiotensin system blockade. Learn how combining SGLT2 inhibitors, nonsteroidal MRAs, GLP-1 receptor agonists, and novel aldosterone synthase or endothelin inhibitors addresses residual cardiorenal risk.
Today
